Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Biosino Bio-Technology and Science's quarterly market cap
declined
from Dec. 2024 (HK$110.0 Mil) to Jun. 2025 (HK$99.8 Mil) but then
increased
from Jun. 2025 (HK$99.8 Mil) to Dec. 2025 (HK$327.0 Mil).
Biosino Bio-Technology and Science's annual market cap
declined
from Dec. 2023 (HK$115.8 Mil) to Dec. 2024 (HK$110.0 Mil) but then
increased
from Dec. 2024 (HK$110.0 Mil) to Dec. 2025 (HK$327.0 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Biosino Bio-Technology and Science's Enterprise Value for Today is HK$600.5 Mil.
Biosino Bio-Technology and Science (HKSE:08247) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Biosino Bio-Technology and Science Market Cap Related Terms
Biosino Bio-Technology and Science Market Cap Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biosino Bio-Technology and Science Market Cap Chart
HKSE:08247 vs TMO, DHR, IDXX: Market Cap Comparison
For the Diagnostics & Research subindustry, Biosino Bio-Technology and Science's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biosino Bio-Technology and Science Market Cap vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Biosino Bio-Technology and Science's Market Cap distribution charts can be found below:
* The bar in red indicates where Biosino Bio-Technology and Science's Market Cap falls into.
Biosino Bio-Technology and Science Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biosino Bio-Technology and Science (HKSE:08247) has a Market Cap of HK$457.3 Mil as of Aug. 21, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Biosino Bio-Technology and Science and its competitors. According to the industry distribution chart, Biosino Bio-Technology and Science ranks #112 out of 216 companies in the Medical Diagnostics & Research industry, placing it in the top 51.9%.
Is Biosino Bio-Technology and Science's Market Cap too high?
Biosino Bio-Technology and Science's current Market Cap is HK$457.3 Mil. Based on the distribution chart, Biosino Bio-Technology and Science ranks #112 out of 216 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Biosino Bio-Technology and Science has a GF Score™ of 37/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Biosino Bio-Technology and Science's Market Cap compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Biosino Bio-Technology and Science ranks #112 out of 216 companies for Market Cap. This places Biosino Bio-Technology and Science in the lower half of its industry. The industry median Market Cap is 63.43. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Medical Diagnostics & Research company?
The median Market Cap among Medical Diagnostics & Research companies is 63.43, based on 216 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Biosino Bio-Technology and Science and its competitors. For the Medical Diagnostics & Research industry, the median Market Cap is 63.43 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biosino Bio-Technology and Science's current Market Cap is HK$457.3 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biosino Bio-Technology and Science stock overvalued right now?
Based on GuruFocus' analysis, Biosino Bio-Technology and Science (HKSE:08247) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$0.44, compared to a current price of HK$3.16 — trading 618.2% above its estimated fair value. The current Market Cap is HK$457.3 Mil. Biosino Bio-Technology and Science's overall GF Score™ is 37/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Biosino Bio-Technology and Science (HKSE:08247), the current Market Cap is HK$457.3 Mil as of Aug. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Biosino Bio-Technology and Science (HKSE:08247) Overvalued in 2026?
Based on GuruFocus' analysis, Biosino Bio-Technology and Science stock appears to be overvalued.
The current stock price of HK$3.16 is trading 618.2% above its estimated GF Value™ of HK$0.44.
GuruFocus considers Biosino Bio-Technology and Science to be Significantly Overvalued.
Key valuation signals for HKSE:08247:
Market Cap: HK$457.3 Mil
GF Value™: HK$0.44 vs. price of HK$3.16 (618.2% above fair value)
No single metric tells the full story. See the HKSE:08247 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Biosino Bio-Technology and Science Inc is engaged in the manufacture, sale, and distribution of IVD reagent products. The company operates in a single segment, the in-vitro diagnostic products segment, which manufactures, sells, and distributes a variety of mono/double diagnostic products. Geographically, it generates the majority of the revenue from Mainland China.
37GF Score
Get the complete analysis for HKSE:08247
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:08247 has been successfully added to your 
